TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04856319
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per-os 2g amoxicillin+clavulanic acid will be administered one hour prior to the surgery
Study: NCT06536166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBM patients treated by placebo, twice a day, during 12 months.
Study: NCT05390489
Drug: Cascara pulp arabica gayo coffee cream
Normalized name: arabica coffee oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: extract of cascara pulp arabica gayo coffee
Study: NCT04908813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Q3W D1
Study: NCT04908813
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO Q3W D1-D14
Study: NCT04947033
Drug: TJ210001 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The test drug TJ210001 will be preset with 5 escalation dose levels: 0.3mg/kg, 1mg/kg, 3mg/kg, 10mg/kg and 15mg/kg, administered once a week.
Study: NCT05089539
Drug: Angiotensin Receptor-Neprilysin Inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan \[100 mg\] bid). Continuous treatment was maintained for at least three months.
Study: NCT05089539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo \[100 mg\] bid). Continuous treatment was maintained for at least three months.
Study: NCT05919394
Drug: To compare in both treatment arms the percentage of patients controlled at week 52.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be assigned to receive one of two therapeutic strategies: the same ICS/LABA combination at the higher doses or the same maintenance treatment at medium doses plus a LAMA.
Study: NCT06669754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06342544
Drug: immediate treatment with corticosteroids
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate standardized treatment with corticosteroids. Standardized treatment in the experimental arm will start at 0.5mg/kg/d prednisone.
Study: NCT04993352
Drug: recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection
Normalized name: endothelial growth factor A, human vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection
Study: NCT05479175
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen
Study: NCT03995004
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.
Study: NCT06502457
Drug: painkiller
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive a painkiller adapted to the service protocol after the fetal heart rate has been recorded.
Study: NCT05787769
Drug: P shot arm ( Autologous Platelet Rich Plasma)
Normalized name: ChoreMate One-Shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Platelet Rich Plasma + placebo tab Each injection session will consist of a total of 10 mL PRP infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum
Study: NCT06377553
Drug: Radiotracer Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous catheter will be placed in an arm or hand vein for injection of \[68Ga\]CBP8;~6-10 mCi of \[68Ga\]CBP8 or 5-9 mCi of FAPI will be injected into the Biograph mMR system. The injected dose and the time of injection will be recorded; The catheter will be flushed with 0.9% saline solution; The subjects will then be positioned on the scanner table; support devices under the back or legs will be used to enable the patient to maintain his/her position throughout the scan comfortably.
Study: NCT06767540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo subcutaneous injection Q2W until week 46.
Study: NCT06767540
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo subcutaneous injection Q3W until week 45.
Study: NCT05195034
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 0.9% saline is administered with the same volume at the same speed as the other group.
Study: NCT05961202
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 20mg qd
Study: NCT05038488
Drug: MIB-626
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fifty participants will be randomized, stratified by sex, remdesivir use, and trial site, in a 3:2 ratio to receive either MIB-626 1.0 g orally or matching placebo twice daily for 14 days.
Study: NCT05038488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive either the placebo or 1000-mg MIB-626 twice daily orally.
Study: NCT04632940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered per schedule specified in the arm description.
Study: NCT04632940
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic deflazacort or equivalent potency of corticosteroids administered orally
Study: NCT06301165
Drug: TPC induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPC induction chemotherapy regimen contains Polymeric micellar paclitaxel, which is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel, cisplatin and capecitabine. TPC induction chemotherapy regimen (polymeric micellar paclitaxel 200 mg/m2 D1, cisplatin 75 mg/m2 D1, capecitabine 1000 mg/m2/day D1-14, every 3 weeks for 3 cycles).
Study: NCT06301165
Drug: GP induction chemotherapy
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP induction chemotherapy regimen (gemcitabine 1000 mg/m2 D1/8, cisplatin 80 mg/m2 D1, every 3 weeks for 3 cycles)
Study: NCT06158633
Drug: Prevora
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevora Stage 1, a topical, intra-oral solution of chlorhexidine acetate 100mg/ml followed immediately by Prevora Stage 2 which is a topical solution of polymethylmethacrylate. Prevora Stage 1 and Prevora Stage 2 are applied topically using a small brush and sequentially to the teeth and gum line of the patient/participant.~All subjects will receive at total 4 applications of Prevora 1 and 2. One on Day 1, 14 days, 3 months and 4 months.
Study: NCT05148884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be matching tablets (identical weight, shape and color) without NLX-112.
Study: NCT05278156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily.
Study: NCT06432738
Drug: ZL-82 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group of subjects take ZL-82 placebo
Study: NCT06147232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05619965
Drug: sedative
Normalized name: Sedative
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexmedetomidine 1 mic/kg IV over 10 minutes then 0.4 mic/kg/h continuous IV infusion
Study: NCT05152186
Drug: Topical Solution
Normalized name: Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration
Study: NCT05152186
Drug: Topical Foam
Normalized name: Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration
Study: NCT05424393
Drug: csDMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: csDMARDs include methotrexate, sulfasalazine, hydroxychloroquine and leflunomide The use of csDMARDs complies with clinical routine practice and treatment strategy of treat-to-target.
Study: NCT05981066
Drug: Neoantigen vaccine, I.M injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a fixed applicable dose of ABOR2014(IPM511) administered.
Study: NCT05881382
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.
Study: NCT05684640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 0mg, BID
Study: NCT05535647
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 2400mg/m2 infusion 48h.
Study: NCT05319860
Drug: Standard of Care Treatment for Chemotherapy Induced Nausea and Vomiting (CINV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for CINV includes anti-nausea medication as needed after chemotherapy regimen given for up to 12 weeks.
Study: NCT05319860
Drug: Aromatherapy Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: An aromatherapy inhaler provided for use as needed after chemotherapy regimen given for up to 12 weeks. One normal inhale is equal to one dose of aromatherapy. Participants can use the aromatherapy as often as needed.
Study: NCT06110546
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive usual care with IV Fentanyl or hydromorphone per hospital protocols
Study: NCT06290128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Route of administration: IV Infusion
Study: NCT06290128
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution Route of administration: SC Injection
Study: NCT06481098
Drug: HM15275
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
Study: NCT06481098
Drug: Placebo of HM15275
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sterile, matching solution supplied in pre-filled syringes.
Study: NCT05458180
Drug: Lposomal mitoxantrone hydrochloride,Cyclophosphamide,Vincristine,Etoposide and Prednisone(CMOEP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Liposomal mitoxantrone hydrochloride (15 mg/m2, 18 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Cyclophosphamide (750 mg/ m2) will be administered by an intravenous infusion on day 1 of each 21-day cycle.~Drug: Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.~Drug: Etoposide (60 mg/ m2) will be administered by an intravenous infusion on day 1-3 of each 21-day cycle.~Drug: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
Study: NCT06667960
Drug: JK06
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Biparatopic anti-5T4 antibody
Study: NCT05023031
Drug: NVP-2102-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet formulation for oral administration, single dose of NVP-2102-R at Day 1
Study: NCT04560179
Drug: Tobramycin solution for inhalation 78mg dose
Normalized name: Tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin - 78mg administered every 12 hours for 14 days.
Study: NCT04560179
Drug: Tobramycin solution for inhalation 150mg dose
Normalized name: Tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin - 150mg administered every 12 hours for 14 days.
Study: NCT04560179
Drug: Tobramycin solution for inhalation 216mg dose
Normalized name: Tobramycin Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin - 216mg administered every 12 hours for 14 days.
Study: NCT04560179
Drug: Tobramycin solution for inhalation 300mg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tobramycin - 300mg administered every 12 hours for 14 days.
Study: NCT06353529
Drug: Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution
Normalized name: bupivacaine-epinephrine 0.5%-1:200,000 injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mL injection bilateral (4mL total) of 0.5% bupivacaine with 1:200,000 epinephrine solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
Study: NCT06353529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mL injection bilateral (4mL total) 0.9% saline solution, 20G needle, sterile, sphenopalatine ganglion; nerve block
Study: NCT05763329
Drug: Placebo Day 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo on the second day of sleep test
Study: NCT05087030
Drug: RGB-14-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive RGB-14-P into the thigh, abdomen, or upper arm as per the arm assigned.
Study: NCT05087030
Drug: Prolia®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Prolia® into the thigh, abdomen, or upper arm as per the arm assigned.
Study: NCT06670963
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg (lower limit for the local laboratory reference range for reticulocyte hemoglobin equivalent)
Study: NCT06670963
Drug: 0.9 % NaCl
Normalized name: dextrose 10 %-0.9 % NaCl MISCELL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume of 0.9% NaCl identical as volume of medications used in experimental arm
Study: NCT06669234
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per the protocol
Study: NCT05205161
Drug: AZD0466
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive treatment with the investigational product AZD0466 via intravenous infusion.
Study: NCT04643769
Drug: ORIN1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet - ORIN1001
Study: NCT04643769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet - placebo
Study: NCT06234995
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will take levodopa in dosages prescribed by their care provider. Patients will be instructed to not take their regularly prescribed PD medications for 12 hours prior to the study assessment, as is typical for clinical evaluations in patients with PD. Participants will be tested in both levodopa-off (after 12 hours of not having medication) and levodopa-on states.
Study: NCT06063473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
Study: NCT06063473
Drug: AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication will be self-applied topically, on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days
Study: NCT06558344
Drug: Placebo matching BI 1569912
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching BI 1569912
Study: NCT05535166
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Route of administration: Intravenously (IV)
Study: NCT05535166
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Route of administration: Intravenously (IV)
Study: NCT06612268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Etavopivat will be administered orally.
Study: NCT06611930
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (liquid for injection, which includes no active ingredient).
Study: NCT02934282
Drug: HBOC-201
Normalized name: Hib (HbOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin Based Oxygen Carrier (HBOC)
Study: NCT05100706
Drug: Sham continuous adductor canal block (ShACB).
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% infusion through adductor canal catheter
Study: NCT05174312
Drug: Diuretic
Normalized name: Diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
Study: NCT06608901
Drug: REGN7544
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per the protocol
Study: NCT06608901
Drug: PB
Normalized name: PBG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per the protocol
Study: NCT04905914
Drug: ATRN-119
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRN-119 is a capsule formulation that will be supplied as 50 mg and 100 mg capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.
Study: NCT05870865
Drug: ASN008
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASN008 topical gel applied twice daily.
Study: NCT04026568
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm
Study: NCT06422182
Drug: Bupivacain 25% (Erector Spinae Plane Block)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received ultrasound guided bilateral single shot erector spinae pane block (ESPB) at Th10 level with 20 mL 0.25% bupivacaine after the end of surgery.
Study: NCT06096025
Drug: pneumoniae bacteremia therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia.
Study: NCT05292755
Drug: Preservative-free, CMC-free Artificial Tears (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A pack of 21 vials of artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be given to subjects in the control group.
Study: NCT05068856
Drug: HRS2543
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalation part For the dose-escalation study, five dose cohorts (25 mg , 75 mg , 150 mg , 300 mg , and 450 mg ) of HRS2543 are initially set.~Dose-expansion part After the completion of dose-escalation study, the dose-expansion study will be carried out at the recommended dose level by the SMC.
Study: NCT04708587
Drug: dual anti-platelet therapy at least 6 months
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.
Study: NCT04708587
Drug: dual anti-platelet therapy 3months or less
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.
Study: NCT06657703
Drug: HC022
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05189444
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5g bid
Study: NCT05733455
Drug: Placebo (microcrystalline cellulose), 2 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will ingest two capsules filled with microcrystalline cellulose at 23:00, along with a saltine cracker.
Study: NCT05642377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral administration
Study: NCT05642377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily oral administration
Study: NCT04733820
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Paclitaxel or docetaxel + Cisplatin or carboplatin Paclitaxel 135-175mg/m2 over 3 hours or docetaxel 70-75 mg/m2， 30min ＋ Cisplatin 75-80mg/m2 or carboplatin AUC = 5, repeat per 21 days.
Study: NCT04052139
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In week 1, participants will take 1 placebo capsule once daily. In week 2, participants will take 1 placebo capsule three times per day. In weeks 3 through 7, 2 placebo capsules three times per day. In week 8, in days 1-4 participants will take 2 placebo capsules three times per day; in days 5-7, participants will take 1 placebo capsule three times per day. The placebo medications will be composed of lactose and will not contain active ingredients.
Study: NCT06162455
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
Study: NCT06162455
Drug: 200- ppm NO
Normalized name: caffeine 200 MG [No Doz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
Study: NCT04673383
Drug: SPL026
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution
Study: NCT04673383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL026-matched placebo
Study: NCT00006187
Drug: Investigational drug
Normalized name: INVESTIGATIONAL DRUGS FOR DEMENTIA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04925960
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsule with be identical in appearance to the Epalrestat capsule. It will contain microcrystalline cellulose filler in a gelatin capsule.
Study: NCT06551623
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin tablets 0.5 g
Study: NCT05122130
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The donor site will be dressed with melatonin loaded gelatin sponge
Study: NCT06090071
Drug: Phyto A+ Brightening Treatment
Normalized name: phytol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyto A+ Brightening Treatment is a serum comprised of a soothing botanical blend matched with a keratolytic (3% azeleic acid), 2.5% niacinamide, a brightening compound (2 % α-arbutin), and botanical extracts
Study: NCT06203002
Drug: Placebo (blinded)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LX9211 matching placebo tablets
Study: NCT06203002
Drug: LX9211 (blinded)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LX9211 (blinded) tablets